{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:38:09Z","timestamp":1783535889304,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.cld.2021.01.010","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T04:15:22Z","timestamp":1615522522000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of Severe and Refractory Ascites"],"prefix":"10.1016","volume":"25","author":[{"given":"H\u00e9l\u00e8ne","family":"Larrue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Vinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2021.01.010_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.1840070124","article-title":"Compensated cirrhosis: natural history and prognostic factors","volume":"7","author":"Gin\u00e9s","year":"1987","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2021.01.010_bib2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2006.08.007","article-title":"Natural history of patients hospitalized for management of cirrhotic ascites","volume":"4","author":"Planas","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.010_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D\u2019Amico","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.01.010_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/gastro\/gox010","article-title":"Ascites, refractory ascites and hyponatremia in cirrhosis","volume":"5","author":"Fortune","year":"2017","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"4","key":"10.1016\/j.cld.2021.01.010_bib5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/hep.28740","article-title":"Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure","volume":"64","author":"Cl\u00e0ria","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2021.01.010_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.05.011","article-title":"Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites","author":"T\u00e9llez","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.01.010_bib7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2021.01.010_bib8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","article-title":"Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis","volume":"94","author":"Gin\u00e8s","year":"1988","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2021.01.010_bib9","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.24786","article-title":"Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials","volume":"55","author":"Bernardi","year":"2012","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2021.01.010_bib10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/gut.2009.193227","article-title":"TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update","volume":"59","author":"R\u00f6ssle","year":"2010","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2021.01.010_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-8278(96)80065-1","article-title":"Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists","volume":"25","author":"Lebrec","year":"1996","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.cld.2021.01.010_bib12","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJM200006083422303","article-title":"A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites","volume":"342","author":"R\u00f6ssle","year":"2000","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2021.01.010_bib13","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/gast.2002.37073","article-title":"Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis","volume":"123","author":"Gin\u00e8s","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2021.01.010_bib14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/gast.2003.50088","article-title":"The North American Study for the treatment of refractory ascites","volume":"124","author":"Sanyal","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2021.01.010_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.20364","article-title":"Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites","volume":"40","author":"Salerno","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.01.010_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00535-010-0282-9","article-title":"Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial","volume":"46","author":"Narahara","year":"2011","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2021.01.010_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2021.01.010_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2021.01.010_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.dld.2016.10.011","article-title":"Consensus conference on TIPS management: techniques, indications, contraindications","volume":"49","author":"Fagiuoli","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2021.01.010_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cld.2011.12.008","article-title":"Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt","volume":"16","author":"Riggio","year":"2012","journal-title":"Clin Liver Dis"},{"issue":"7","key":"10.1016\/j.cld.2021.01.010_bib21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cgh.2018.01.029","article-title":"Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis","volume":"16","author":"Schepis","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.01.010_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jvir.2016.06.023","article-title":"Prospective evaluation of passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stent grafts-a three-dimensional sonography study","volume":"28","author":"Pieper","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.cld.2021.01.010_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00270-018-2040-y","article-title":"Transjugular intrahepatic portosystemic shunt using the new Gore Viatorr controlled expansion endoprosthesis: prospective, single-center, preliminary experience","volume":"42","author":"Miraglia","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.cld.2021.01.010_bib24","doi-asserted-by":"crossref","DOI":"10.7326\/M20-0202","article-title":"The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial","author":"Bureau","year":"2021","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.cld.2021.01.010_bib25","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/hep.30934","article-title":"A\u00a0prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the Toulouse algorithm","volume":"70","author":"Billey","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2021.01.010_bib26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2017.06.010","article-title":"Alfapump\u00ae system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study","volume":"67","author":"Bureau","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.01.010_bib27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/lt.25724","article-title":"Improvement in quality of life and decrease in large-volume paracentesis requirements with the automated low-flow ascites pump","volume":"26","author":"Wong","year":"2020","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.cld.2021.01.010_bib28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2012.12.020","article-title":"Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study","volume":"58","author":"Bellot","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2021.01.010_bib29","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/apt.15502","article-title":"Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites","volume":"50","author":"Lepida","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cld.2021.01.010_bib30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/lt.24763","article-title":"Effects of alfapumpTM system on kidney and circulatory function in patients with cirrhosis and refractory ascites","volume":"23","author":"Sol\u00e0","year":"2017","journal-title":"Liver Transpl"},{"issue":"10138","key":"10.1016\/j.cld.2021.01.010_bib31","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2021.01.010_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.13968","article-title":"Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites","volume":"39","author":"Di Pascoli","year":"2019","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2021.01.010_bib33","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting LT. A randomized placebo-controlled trial","volume":"69","author":"Sol\u00e0","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.01.010_bib34","article-title":"On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites","author":"Caraceni","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.010_bib35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MEG.0000000000001277","article-title":"Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study","volume":"31","author":"Yosry","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2021.01.010_bib36","doi-asserted-by":"crossref","first-page":"5106958","DOI":"10.1155\/2020\/5106958","article-title":"Role of terlipressin in cirrhotic patients with ascites and without hepatorenal syndrome: a systematic review of current evidence","volume":"2020","author":"Bai","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2021.01.010_bib37","unstructured":"Carbonell N, Louvet A, Rousseau A, et\u00a0al. Terlipressine plus albumine versus albumine seule chez des patients atteints de cirrhose avec ascite r\u00e9fractaire trait\u00e9s par paracent\u00e8se: essai prospectif multicentrique fran\u00e7ais randomis\u00e9 contre placebo (essai TERAS). R\u00e9sum\u00e9 n\u00b0CO-034 AFEF 2017 Nice."},{"issue":"1","key":"10.1016\/j.cld.2021.01.010_bib38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/gutjnl-2011-300157","article-title":"Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2021.01.010_bib39","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/liv.13250","article-title":"Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study","volume":"37","author":"Rai","year":"2017","journal-title":"Liver Int"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:58:21Z","timestamp":1761069501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326121000106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1089326121000106"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2021.01.010","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Severe and Refractory Ascites","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2021.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}